-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Clinical Trials
Clinical TrialsSanofi and Regeneron Announce Positive Results from Phase III Trial in Eosinophilic Esophagitis
Sanofi and Regeneron Announce Positive Results from Phase III Trial in Eosinophilic EsophagitisSanofi and Regeneron announced positive results from this tria.
Supervision
SupervisionBiogen Tofersen Receives FDA Priority Review for Treatment of Rare Hereditary Amyotrophic Lateral Sclerosis
Biogen Tofersen Receives FDA Priority Review for Treatment of Rare Hereditary Amyotrophic Lateral SclerosisThe .
ACADIA Pharmaceuticals Submits New Drug Application to FDA for Trofinetide for Rett Syndrome
ACADIA Pharmaceuticals Submits New Drug Application to FDA for Trofinetide for Rett SyndromeTrofinetide (NNZ 2566) is a small molecule analog of its proprietary glycine-proline-glutamic acid (Glypromate) being developed by Neuren Pharmaceuticals for the treatment of brain injury, Rett syndrome and Fragile X syndrome, among others diseas.
trade
tradeGinkgo Bioworks to acquire Zymergen for $300 million
Ginkgo Bioworks to acquire Zymergen for $300 millionGinkgo Bioworks and Zymergen announced that they have reached a definitive agreemen.
Nestlé Health Science partners with Enterome to develop new treatments for food allergies and inflammatory bowel disease
Nestlé Health Science partners with Enterome to develop new treatments for food allergies and inflammatory bowel diseaseEnterome has entered into an R&D agreement with Nestlé Health Sciences to develop and commercialize novel immunotherapies for food allergy and inflammatory bowel diseas.
LegoChem Biosciences partners with Glycotope to develop an antibody-drug conjugate
LegoChem Biosciences partners with Glycotope to develop an antibody-drug conjugateLegoChem Biosciences and Glycotope have entered into a research collaboration and license agreement to combine LCB's exclusive Antibody Drug Conjugate (ADC) technology with one of Glycotope's investigational tumor-targeting antibodies to develop an Antibody Drug Conjugate (ADC.
Orion Biotechnology and Peptilogics Collaborate on AI-Driven Drug Discovery for GPCR Targets Not Yet Targeted
Orion Biotechnology and Peptilogics Collaborate on AI-Driven Drug Discovery for GPCR Targets Not Yet TargetedOrion Biotechnology Canada has entered into an R&D collaboration with Peptilogics to use artificial intelligence (AI) for drug discovery targeting a G-protein-coupled receptor (GPCRs) target that has not yet been targeted for drug.
Boehringer Ingelheim, Evotec and bioMérieux form joint venture Aurobac to tackle antimicrobial resistance
Boehringer Ingelheim, Evotec and bioMérieux form joint venture Aurobac to tackle antimicrobial resistanceBoehringer Ingelheim, Evotec SE and bioMérieux SA have announced a joint venture to develop next-generation antimicrobials and actionable diagnostics to combat antimicrobial resistance (AMR.
Pfizer and Touchlight Reach Patent License Agreement for dbDNA for mRNA Vaccines, Drugs and Gene Therapies
Pfizer and Touchlight Reach Patent License Agreement for dbDNA for mRNA Vaccines, Drugs and Gene TherapiesTouchlight announces a non-exclusive patent license agreement with Pfize.
Mogrify partners with Astellas to tackle sensorineural deafness
Mogrify partners with Astellas to tackle sensorineural deafnessCell Mogrify has entered into a collaborative research agreement with Astellas to conduct research on in vivo regenerative medicine approaches for the treatment of sensorineural hearing los.
Sanofi and Skyhawk collaborate on oncology and immunology targets
Sanofi and Skyhawk collaborate on oncology and immunology targetsSkyhawk Therapeutics and Sanofi enter into a collaborative agreement to discover and develop novel small molecules that modulate RNA splicing for challenging oncology and immunology target.
About AdisInsight
About AdisInsightAdisInsight is a comprehensive scientific data-based database containing information on drug development, clinical trials, adverse drug events, commercial transactions, and patents, dedicated to helping customers accurately, comprehensively, and cost-effectively monitor the growing number of investigational drug candidate.
